Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

In this week's podcast version of Five Must-Know Things, hear about new results for Lilly in Alzheimer’s, a US delay for AbbVie, progress for Zolgensma in the UK, challenges for AstraZeneca’s coronavirus vaccine, and a Scrip roundtable on industry lessons from the pandemic.

Join us for an audio catch-up on the major events in the biopharma industry in the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 19 March 2021, including: new results for Lilly in Alzheimer’s; a US delay for AbbVie; progress for Zolgensma in the UK; challenges for AstraZeneca’s coronavirus vaccine; and a Scrip roundtable on lessons from the pandemic.

These and all other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud and TuneIn - and also now on Spotify Podcasts - and via smart speakers if one of these platforms has been set up as your default podcast provider. 

Stories mentioned in this episode:

(Also see "Lilly’s New Anti-Amyloid Play Hinges On Tau Bet" - Scrip, 15 Mar, 2021.)

(Also see "AbbVie’s Rinvoq Delay By US FDA Could Foreshadow More Trouble For JAKs" - Scrip, 17 Mar, 2021.)

(Also see "Novartis Steers Zolgensma Towards Commercial Success In Europe" - Scrip, 12 Mar, 2021.)

(Also see "AstraZeneca’s COVID-19 Vaccine PR Nightmare Won’t Faze Investors" - Scrip, 16 Mar, 2021.)

(Also see "Pandemic Perspectives: R&D Lessons Learned From The COVID Year" - Scrip, 17 Mar, 2021.)


Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts